Sun Pharma acquires Disperzyme and Phlogam brands to strengthen its anti-inflammatory portfolio
Disperzyme and Phlogam are fixed-dose combinations of proteolytic enzymes and bioflavonoid viz Tryspin, Bromelain and Rutoside (TBR)
Sun Pharma today acquired three brands viz Disperzyme (Trypsin BP 96 mg, Bromelain 180 mg and Rutoside Trihydrate 200 mg), Disperzyme-CD (Trypsin BP 48 mg, Bromelain 90 mg and Rutoside Trihydrate 100 mg) and Phlogam (Trypsin BP 48 mg, Bromelain 90 mg and Rutoside Trihydrate 100 mg) from Aksigen Hospital Care, a Mumbai-based research-driven healthcare entity with over two decades of experience in the healthcare field. All the brands are approved by the Drugs Controller General of India (DCGI) for post-operative inflammation in patients undergoing minor surgery and dental procedures, according to a company statement.
All the brands are approved by the Drugs Controller General of India (DCGI) for post-operative inflammation in patients undergoing minor surgery and dental procedures, said the statement.
Disperzyme and Phlogam are the first enzyme-bioflavonoid combination of Trypsin, Bromelain and Rutoside (TBR) to complete a clinical study in India and get DCGI approval. The brands were registered and launched in India by Aksigen in 2013, added the statement.